Dr. Alicia Morgans of Dana-Farber Cancer Institute reported at #ASCO26 that ARACOG found darolutamide was associated with less decline in cognitive testing than enzalutamide, which may help guide treatment choice.

Related Presenters

Alicia Morgans, MD, MPH

Medical Oncology

View full profile